Filing Flows

Filing Flows › AbbVie (ABBV) › Next earnings date

AbbVie (ABBV) earnings: beat the estimate

AbbVie (ABBV) reported on Oct 30, 2026 and beat the EPS estimate: $3.82 against $3.76 (+1.5%). Revenue was $17.4B for Q3 2026, +10% year over year. The stock moved -0.7% on the report. It beat the EPS estimate in 80% of the quarters on record.

Last result+1.5% vs estimate
Beat rate80%

The last report

AbbVie reported revenue of $17.4B for the third quarter 2026 (+10% Y/Y), net earnings $4.2B. How it makes money → · Every quarter →

AbbVie: EPS against the estimate, last 5 reportsAbbVie: EPS against the estimate, last 5 reportsEstimateReported$1.78$1.86Oct 25$2.65$2.71Feb 26$2.67$2.65Apr 26$3.61$3.65Jul 26$3.76$3.82Oct 26
Latest (Oct 26): Estimate $3.76, Reported $3.82.
ABBV: the stock's move on each reportABBV: the stock's move on each reportOct 30, 2026-0.7%Jul 31, 2026-4.8%Apr 29, 2026+6.9%Feb 4, 2026-2.9%Oct 31, 2025-7.1%

AbbVie's latest quarter

AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%, net earnings $4.2B, operating cash flow $7.6B. The chart follows the revenue to costs, profit and cash.

Questions

Did AbbVie beat earnings?

AbbVie (ABBV) reported on Oct 30, 2026 and beat the EPS estimate: $3.82 against $3.76 (+1.5%).

When does ABBV report earnings?

The next date is not set yet.

Does AbbVie usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.